Microparticle containing matrices for drug delivery
View Patent ↗Polymeric matrices including microparticles that provide sustained release of a hydrophilic bioactive agent are described. The matrices can be in the form of a coating on the surface of an implantable medical article or an in situ formed matrix. The microparticles of the matrix include a first polymer and a second polymer that modulates release of the hydrophilic bioactive agent from the matrix.
1. A matrix which releases bioactive agent at a target location in the body where it is implanted or formed in situ, wherein the matrix is formed of a polymeric material that allows fluid to penetrate the matrix, and the matrix comprises at least one set of microparticles immobilized in the matrix, said microparticles comprising, 1) a water-soluble bioactive agent, 2) a first polymer, and 3) a second polymer, wherein one or both first and second polymers are hydrophobic being not soluble in water, and wherein one or both first and second polymers comprise a polysaccharide derivatized with hydrophobic moieties, wherein the second polymer modulates release of the bioactive agent from the matrix as compared to release of the bioactive agent from a matrix comprising microparticles that do not include the second polymer.
2. The matrix of claim 1 wherein the water-soluble bioactive agent comprises an ionizable molecule.
3. The matrix of claim 1 wherein the water-soluble bioactive agent has a molecular weight of less than 1000 Da.
4. The matrix of claim 1 wherein the water-soluble bioactive agent is selected from the group consisting of polypeptides, polysaccharides, and polynucleotides.
5. The matrix of claim 1 wherein the polymeric material comprises reacted groups that covalently couple the polymeric material together, covalently couple the polymeric material to a surface of a device, or both.
6. The matrix of claim 5 wherein the reacted groups comprise photoreactive groups.
7. The matrix of claim 1 wherein the polymeric material comprises a polymer that is more biostable than the first or second polymers of the microparticle.
8. The matrix of claim 1 wherein the polymeric material comprises a synthetic hydrophilic polymer.
9. The matrix of claim 8 wherein the synthetic hydrophilic polymer comprises hydroxyethyl methacrylate, hydroxyethyl acrylate, methacrylic acid, acrylic acid, glycerol acrylate, glycerol methacrylate, acrylamide, methacrylamide, dimethylacrylamide (DMA), vinyl acetate, vinylpyrrolidone, vinyl alcohol, ethylene oxide, propylene oxide, butylene oxide, or combinations thereof.
10. The matrix of claim 1 wherein the first and second polymer include the same type of monomeric residue.
11. The matrix of claim 1 wherein the second polymer comprises a biodegradable homopolymer.
12. The matrix of claim 1 wherein the microparticles comprise an inner core comprising the bioactive agent and the first polymer, and an outer shell comprising the second polymer.
13. The matrix of claim 1 wherein the microparticles have a size of 50 μm or less.
14. The matrix of claim 1 which is in the form of a in situ-formed hydrogel.
15. The matrix of claim 1 which is in the form of a coating on the surface of an implantable medical device.
16. The matrix of claim 1 which is in the form of a coating on the surface of an implantable ocular device.
17. The matrix of claim 1 wherein the water-soluble bioactive agent has a molecular weight of more than 1,000 Da.
18. The matrix of claim 1 wherein the water-soluble bioactive agent is an antibody.
19. The matrix of claim 1 wherein the first and/or second polymer comprises a polysaccharide selected from the group consisting of maltodextrin, amylose, and polyalditol that is derivatized with hydrophobic moieties.
20. The matrix of claim 1 , wherein the hydrophobic moieties are selected from C 2 -C 18 linear, branched, or cyclic alkyl groups.
21. The matrix of claim 20 , wherein the hydrophobic moieties are selected from C 2 -C 10 linear, branched, or cyclic alkyl groups.
22. The matrix of claim 21 , wherein the hydrophobic moieties are selected from C 2 -C 6 linear, branched, or cyclic alkyl groups.
23. The matrix of claim 1 wherein the polysaccharide is derivatized with hydrophobic moieties at a degree of substitution of greater than 1.
24. A matrix which releases bioactive agent at a target location in the body where it is implanted or formed in situ, wherein the matrix is formed of a polymeric material that allows fluid to penetrate the matrix, and the matrix comprises at least one set of microparticles immobilized in the matrix, said microparticles comprising, 1) a water-soluble bioactive agent, 2) a first polymer, and 3) a second polymer, wherein first and second polymers are hydrophobic being not soluble in water, and said first and second polymers comprise a polysaccharide selected from the group consisting of maltodextrin, amylose, and polyalditol derivatized with hydrophobic moieties at a degree of substitution of greater than 1, wherein the hydrophobic moieties are selected from C 2 -C 18 linear, branched, or cyclic alkyl groups, and wherein the second polymer modulates release of the bioactive agent from the matrix as compared to release of the bioactive agent from a matrix comprising microparticles that do not include the second polymer.